Quantitation of a novel antiemetic (ADR-851) in plasma and urine by reversed-phase high-performance liquid chromatography with fluorescence detection.
A sensitive and specific bioanalytical method for quantitation of a novel antiemetic (ADR-851) in plasma and urine has been developed and validated. The drug and internal standard (metoclopramide) are extracted from the plasma matrix by solid-phase extraction on cyanopropyl bonded-phase columns. After extraction, samples are separated by isocratic reversed-phase high-performance liquid chromatography. The parent drug, internal standard and a yet unidentified metabolite are detected by fluorescence. The method requires 1.0 ml of plasma or 0.1 ml of urine and has a lower limit of quantitation of 2 ng/ml with 10.9% relative standard deviation (R.S.D.). Method linearity has been established over a 2-800 ng/ml range when 1.0 ml of plasma is used. The intra- and inter-day imprecisions for the method are typically better than 6% and 11% R.S.D., respectively, in both plasma and urine over the entire dynamic range. The pooled estimate of bias is less than 5% and attests to the excellent accuracy.
Rossi
D T
DT
Department of Pharmacokinetics/Dynamics, Adria Laboratories, Division of Erbamont, Dublin, OH 43017.
Overmyer
S K
SK
Lewis
R C
RC
Narang
P K
PK
D000932:Antiemetics / Q000032:analysis* / Q000097:blood / Q000652:urine; D002851:Chromatography, High Pressure Liquid / Q000379:methods* / Q000592:standards / Q000706:statistics & numerical data; D004355:Drug Stability; D006801:Humans; D008787:Metoclopramide / Q000031:analogs & derivatives* / Q000032:analysis / Q000097:blood / Q000652:urine; D011786:Quality Control
D000932:Antiemetics; C070662:ADR 851; D008787:Metoclopramide